Hema-NeoTIL01 Cell Infusion Therapy(The First Affiliated Hospital Of Soochow University)

N/A

Report date: 2026/04/17 10:36:36

Base Information

Drug NameHema-NeoTIL01 Cell Infusion Therapy(The First Affiliated Hospital Of Soochow University)
Drug Alias Nametumor infiltrating lymphocyte (TIL) product derived from patients' bone marrow or peripheral blood(The First Affiliated Hospital Of Soochow University)Hema-NeoTIL01
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsLeukemia, Myeloid, AcutePrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesThe First Affiliated Hospital Of Soochow University
China Registration ClassN/A

Develop Information

Active CompaniesThe First Affiliated Hospital Of Soochow University
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, AcutePrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A